The landscape of treatment options and outcomes for patients with locally advanced and
metastatic melanoma has changed dramatically in the past decade, with the introduction of …

Stage III melanoma encompasses a range of disease burdens, including microscopic foci of
metastatic melanoma in a sentinel lymph node; bulky, clinically detected lymphadenopathy; …

Introduction: In recent years, the introduction of targeted therapy and immunotherapy into
clinical practice has radically changed the management of advanced melanoma. More …

Simple Summary The current standard of care for locally advanced melanoma is surgery first
followed by systemic therapy. However, there is growing evidence that neoadjuvant therapy …

The discovery of immunotherapy and targeted therapy has introduced new and effective
treatment options for advanced melanoma, providing therapeutic options where none …

There will be an estimated 76,100 new cases of melanoma diagnosed in 2015 and 9710
deaths. Patients with stage I/II disease have excellent outcomes, and the treatment …

Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that
ranges from approximately 40% to 90% at 5 years following surgical management alone …

Adjuvant systemic therapy for cutaneous melanoma has experienced practice‐changing
shifts over the last decade. The successful results of immunotherapies and targeted …

Locally/regionally advanced melanoma confers a major challenge in terms of surgical and
medical management. Surgical treatment carries the risks of surgical morbidities and …

Opinion statement Patients with clinical stage III melanoma, defined as palpable lymph
nodes with or without in-transit metastases, have poor prognosis even with recent advances …